Paraneoplastic neutrophilic leukemoid reaction in a melanoma patient: association between tumour volume and leukocytosis

Melanoma and Skin Cancer

Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

Melanoma Res.

Plaquevent M, Greliak A, Pinard C, Duval-Modeste AB, Joly P

doi: 10.1097/CMR.

Melanoma and Skin Cancer

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

Melanoma Res.

Kosche C, Stout M, Sosman J, Lukas RV, Choi JN

doi: 10.1097/CMR.0000000000000642.

Melanoma and Skin Cancer

Multiple primary melanoma with the Meyerson phenomenon in a young patient

Melanoma Res.

Fernández-Sartorio C, Alós L, García-Herrera A, Ferrando J, Carrera C

doi: 10.1097/

Melanoma and Skin Cancer

Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature

Melanoma Res.

Zafar FS, Richey P, Okereke U, Milhem M, Abid R, Powers JG, Swick B

doi: 10.1097/CMR.0000000000000713.Visit the original publication at ncbi.nlm.nih.gov

Melanoma and Skin Cancer

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

Melanoma Res.

Thummalapalli R, Melms JC, Mier J, Izar B

doi: 10.1097/CMR.0000000000000646.

Hypersensitivity

[Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors]

Ann Dermatol Venereol.

Rohmer E, Scrivener JN, Schissler C, Cribier B, Lenormand C

doi: 10.1016/j.annder.2019.08.012.

Melanoma and Skin Cancer

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

J Immunother.

Anastasopoulou A, Papaxoinis G, Diamantopoulos P, Christofidou E, Benopoulou O, Stratigos A, Gogas H

Melanoma and Skin Cancer

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Melanoma Res.

Hanna DL, Law SJ, Merrick SA, Heptinstall L, Bass P, Dupont P, Sheri A

doi: 10.1097/CMR.0000000000000651.

Melanoma and Skin Cancer

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature

Melanoma Res.

Dudda M, Mann C, Heinz J, Schmidgen I, Weid F, Kühn M, Saloga J, Grabbe S, Loquai C

doi: 10.1097/CMR.0000000000000703.Visit the original publication at ncbi.nlm.nih.gov

Related content

Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy

Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature

Multiple primary melanoma with the Meyerson phenomenon in a young patient

Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature

Rapid evolution of acute kidney injury after initial infusion of pembrolizumab in a melanoma patient concurrently treated with RAF/MEK inhibitors

[Tattoo hypersensitivity reaction in a patient receiving combined BRAF and MEK inhibitors]

Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature